trending Market Intelligence /marketintelligence/en/news-insights/trending/E6onCIzOF9Igx0p3nAeeHg2 content esgSubNav
In This List

US patent body initiates review of 2 patents for Sanofi's diabetes drug


Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound


According to Market Intelligence, December 2022


Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes


Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

US patent body initiates review of 2 patents for Sanofi's diabetes drug

Mylan NV said the U.S. Patent and Trademark Appeal Board initiated inter partes review proceedings on two patents owned by France-based Sanofi for its diabetes drug Lantus.

The inter partes review is a trial proceeding conducted to review the patentability of claims of an issued patent.

Lantus, or insulin glargine, is a long-acting basal insulin analogue, used to help control the blood sugar level of patients with diabetes.

The U.S. Food and Drug Administration is reviewing a new drug application filed by Mylan for insulin glargine in vial and pen dosage forms.

Previously, Sanofi sued Mylan in a New Jersey court alleging infringement of 18 patents related to Lantus and Lantus SoloStar.

Sanofi has also filed a lawsuit against Merck & Co. Inc. for infringing on two of Lantus patents, after the U.S. drugmaker submitted a new drug application for an insulin glargine vial drug product.

Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. already market an insulin glargine injection under the name Basaglar, which has an identical amino acid sequence to Lantus.

Lilly and Sanofi have signed a patent settlement agreement that allowed Basaglar to be available in the U.S. in 2016.